

**Efficacy of Shexiang Baoxin Pill combined with western medicine in the treatment of coronary heart disease: a Systematic Review and Meta-Analysis**

INPLASY2024110050

doi: 10.37766/inplasy2024.11.0050

Received: 10 November 2024

Published: 10 November 2024

Wang, WX; Shi, FT; Sun, ZL.

**Corresponding author:**

wang wenxuan

wx1289220451@126.com

**Author Affiliation:**

Changchun University of Chinese Medicine.

**ADMINISTRATIVE INFORMATION****Support** - National Natural Science Foundation of China 611.**Review Stage at time of this submission** - Preliminary searches.**Conflicts of interest** - None declared.**INPLASY registration number:** INPLASY2024110050**Amendments** - This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 10 November 2024 and was last updated on 10 November 2024.**INTRODUCTION**

**Review question / Objective** Relevant surveys show that the incidence of coronary heart disease is increasing year by year, which has a great impact on people's lives and reduces the quality of life, in this context, musk cardioprotection pills in combination with conventional western drugs for the treatment of coronary heart disease is getting more and more attention, and the purpose of the present systematic evaluation is to accurately evaluate the musk cardioprotection pills in combination with conventional Western drugs for the treatment of coronary heart disease.

The purpose of this systematic evaluation is to accurately evaluate the efficacy of musk heart pill combined with conventional western drugs in treating coronary heart disease.

P: Patients with coronary heart disease

I: Musk cardioprotective pills combined with conventional western drugs

C: conventional western medicine

O: Effective rate, adverse event rate

S: RCT or cohort study.

**Condition being studied** Relevant surveys show that the incidence of coronary heart disease is increasing year by year, which has a great impact on people's lives and reduces the quality of life, in this context, musk cardioprotection pills in combination with conventional western drugs for the treatment of coronary heart disease is getting more and more attention, and the purpose of the present systematic evaluation is to accurately evaluate the musk cardioprotection pills in combination with conventional Western drugs for the treatment of coronary heart disease.

**METHODS**

**Search strategy** We searched CNKI, WanFang Data, Vip database, CBNdisc and Cochrane Library. Library, Embase, and pubmed, and the English search keywords were "Shexiang Baoxin Pill", "Heart Attack" and "Pill". The English search terms were "Shexiang Baoxin Pill", "Heart Attack",

“Coronary Heart D”, and the Chinese search terms were “musk”, “musk” and “coronary heart”.

“Coronary Heart D”, ‘heart-protecting musk pill’ in Chinese, ‘Musk Baoxin Pill’, ‘Heart Attack’, ‘Coronary Heart D’, ‘Heart Disease’, ‘Coronary Heart Disease’, ‘Coronary Heart Disease’, ‘Coronary Heart Disease’, ‘Coronary Heart Disease’. ”, “coronary heart disease”.Combination of subject words and free wordsThe time limit for searching was from the database construction to November 10, 2024, which was the first time the database was constructed. The search was carried out on manual search of the references accompanying the literature reviewed at this stage.If the literature was not well reported or information was missing, the corresponding author was contacted for access.In case of missing reports or information in the literature, the corresponding authors were contacted to obtain the information.

Search: (((Shexiang Baoxin) OR (heart-protecting musk pill)) AND (((Western medicine) OR (trimetazidine)) OR (atorvastatin))) AND (((((((Coronary Diseases) OR (Disease, Coronary)) OR (Diseases, Coronary)) OR (Coronary Heart Disease)) OR (Coronary Heart Diseases)) OR (Disease, Coronary Heart)) OR (Diseases, Coronary Heart)) OR (Heart Disease, Coronary)) OR (Heart Diseases, Coronary)) OR ("Coronary Disease"[Mesh])).

**Participant or population** Patients with coronary heart disease.

**Intervention** Musk cardioprotective pills combined with conventional western drugs.

**Comparator** Conventional western medicine.

**Study designs to be included** RCT or cohort study.

**Eligibility criteria** Inclusion criteria: patients with coronary artery disease diagnosed by CT, MRI and physicians' clinical diagnosis; intervention: patients in the experimental group (or observation group) should be treated with Musk Cardioprotection Pill combined with conventional Western medicine, and patients in the reference group (or control group) should be treated with conventional Western medicine only; the evaluation criteria were hs-CRP, cardiovascular event rate and mortality rate; the type of the study was RCT; and there was no limitation of the literature's language.

Exclusion criteria: the literature was non-clinical studies, reviews and case reports; the data in the literature were inaccurate, missing or without data expression; if there were duplicates in the literature, the one with the most comprehensive

data was selected, and other duplicates were excluded.

**Information sources** CNKI, WanFang Data, Vip database, CBNdisc and Cochrane Library, Embase, pubmed,web of science.

**Main outcome(s)** Efficient.

**Additional outcome(s)** Adverse Events.

**Data management** EndNote.

**Quality assessment / Risk of bias analysis** Cochrane TOOL.

**Strategy of data synthesis** Apply RevMan 5.3 software to conduct Meta-analysis on the selected relevant literature to detect the heterogeneity of the literature, if  $P > 0.1$ ,  $I^2 > 50\%$ , it means that there is heterogeneity among the studies, analyze the source of heterogeneity, and if the results are still heterogeneous, then analyzed by random-effects model. Analysis. Weighted mean difference (WMD) was used as an indicator of the combined effect size, and the ratio of ratios (OR) was used as the count data.

**Subgroup analysis** Subgroups of patients were studied according to the type and dose of Western medication they were taking, their age, marital status, economic circumstances, etc.

**Sensitivity analysis** After deleting any one of the documents, the combined results of the remaining documents were not significantly different from those without deletion, which means that the sensitivity analysis was passed, and vice versa.

**Country(ies) involved** China.

**Keywords** Shexiang Baoxin Pill;Western medicine; Coronary Disease.

**Contributions of each author**

Author 1 - wang wenxuan.

Email: wwx1289220451@126.com

Author 2 - shi fengtong.

Author 3 - sun zongle.